Literature DB >> 6274207

Ca2+ mobilization in blood platelets as visualized by chlortetracycline fluorescence.

N E Owen, G C Le Breton.   

Abstract

Binding of intracellular Ca2+ was measured in intact human blood platelets using the fluorescent Ca2+ probe, chlortetracycline, and a photon-counting microspectrofluorometer. Low doses of epinephrine, A23187, or prostaglandin endoperoxide analog U46619 induced a release of intraplatelet membrane-bound Ca2+. When platelet transmembrane Ca2+ flux was blocked by verapamil or ethylenediaminetetraacetic acid (EDTA), Ca2+ mobilization in response to epinephrine was inhibited, whereas A23187- or U46619-induced Ca2+ release was unchanged. When indomethacin was used to inhibit cyclo-oxygenase activity, Ca2+ mobilization in response to epinephrine or U46619 was partially blocked, whereas Ca2+ release in response to A23187 was unaltered. The relationship between platelet cyclic adenosine 3',5'-monophosphate (cAMP) and intraplatelet Ca2+ binding was also investigated. Prostaglandin E1 or prostacyclin was found to markedly elevate cAMP as well as enhance platelet Ca2+ binding. These effects were augmented by inhibition of phosphodiesterase activity using RO201724. The relationship between cAMP and Ca2+ binding was linear in the range of 10-60 pmoles cAmP/ml platelet-rich plasma. In addition the increase in cAMP stimulated by prostaglandin E1 or prostacyclin reduced the ability of epinephrine, A23187, or U46619 to induce intraplatelet Ca2+ mobilization.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6274207     DOI: 10.1152/ajpheart.1981.241.4.H613

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

Review 1.  The potential role of thromboxane inhibitors in preventing myocardial ischaemic injury.

Authors:  J L Mehta; W W Nichols
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

2.  [Relation between post-thrombotic syndrome, ADP-induced thrombocyte aggregation and intrathrombocyte calcium content].

Authors:  B Heintz; C Femers; N Maurin; H Kierdorf; C Brilon; V Wienert
Journal:  Klin Wochenschr       Date:  1989-12-04

3.  Proceedings of the British Pharmacological Society 8th-10th September, 1982. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1982-12       Impact factor: 8.739

4.  Comparative platelet anti-aggregant activity of D-cysteinolic acid analogues.

Authors:  M Sataka; Y Chiba; Y Kohama; K Yamamoto; M Okabe; T Mimura; T Imanishi; C Iwata
Journal:  Experientia       Date:  1989-12-01

5.  Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium.

Authors:  W K Pollock; R A Armstrong; L J Brydon; R L Jones; D E MacIntyre
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

6.  Effects of alcohols on ADP-induced aggregation and membrane fluidity of gel-filtered bovine blood platelets.

Authors:  S Kitagawa; T Shinohara; F Kametani
Journal:  J Membr Biol       Date:  1984       Impact factor: 1.843

7.  Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine.

Authors:  K V Honn; J M Onoda; C A Diglio; M M Carufel; J D Taylor; B F Sloane
Journal:  Clin Exp Metastasis       Date:  1984 Jan-Mar       Impact factor: 5.150

8.  Ca2+ mobilization primes protein kinase C in human platelets. Ca2+ and phorbol esters stimulate platelet aggregation and secretion synergistically through protein kinase C.

Authors:  W Siess; E G Lapetina
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

9.  Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation.

Authors:  M M Billah; E G Lapetina
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

10.  Ionic changes in the mitotic apparatus at the metaphase/anaphase transition.

Authors:  S M Wolniak; P K Hepler; W T Jackson
Journal:  J Cell Biol       Date:  1983-03       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.